Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2

This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response. In a longitudinal assay, 346 people (117 with prior COVID-19 and 229 without prior COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Bello, Jorge, Morales-Núñez, José Javier, Machado-Sulbarán, Andrea Carolina, Díaz-Pérez, Saúl Alberto, Torres-Hernández, Paola Carolina, Balcázar-Félix, Paulina, Gutiérrez-Brito, Jesús Alberto, Lomelí-Nieto, José Alvaro, Muñoz-Valle, José Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472849/
https://www.ncbi.nlm.nih.gov/pubmed/34579284
http://dx.doi.org/10.3390/vaccines9091047

Ejemplares similares

Ejemplares similares